Journal article
Two-year outcomes following a randomised platelet transfusion trial in preterm infants
- Abstract:
- Objective: Assess mortality and neurodevelopmental outcomes at 2 years of corrected age in children who participated in the PlaNeT-2/MATISSE (Platelets for Neonatal Transfusion - 2/Management of Thrombocytopenia in Special Subgroup) study, which reported that a higher platelet transfusion threshold was associated with significantly increased mortality or major bleeding compared to a lower one. Design: Randomised clinical trial, enrolling from June 2011 to August 2017. Follow-up was complete by January 2020. Caregivers were not blinded; however, outcome assessors were blinded to treatment group. Setting: 43 level II/III/IV neonatal intensive care units (NICUs) across UK, Netherlands and Ireland. Patients: 660 infants born at less than 34 weeks' gestation with platelet counts less than 50×109/L. Interventions: Infants were randomised to undergo a platelet transfusion at platelet count thresholds of 50×109/L (higher threshold group) or 25×109/L (lower threshold group). Main outcomes measures: Our prespecified long-term follow-up outcome was a composite of death or neurodevelopmental impairment (developmental delay, cerebral palsy, seizure disorder, profound hearing or vision loss) at 2 years of corrected age. Results: Follow-up data were available for 601 of 653 (92%) eligible participants. Of the 296 infants assigned to the higher threshold group, 147 (50%) died or survived with neurodevelopmental impairment, as compared with 120 (39%) of 305 infants assigned to the lower threshold group (OR 1.54, 95% CI 1.09 to 2.17, p=0.017). Conclusions: Infants randomised to a higher platelet transfusion threshold of 50×109/L compared with 25×109/L had a higher rate of death or significant neurodevelopmental impairment at a corrected age of 2 years. This further supports evidence of harm caused by high prophylactic platelet transfusion thresholds in preterm infants. Trial registration number: ISRCTN87736839
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 458.0KB, Terms of use)
-
- Publisher copy:
- 10.1136/archdischild-2022-324915
- Publication website:
- https://ueaeprints.uea.ac.uk/91652/1/archdischild_2022_324915.full.pdf
Authors
+ NHS
Blood and Transplant
More from this funder
- Funder identifier:
- 10.13039/100009033
- Grant:
- BS06/1
+ Health
Service Executive
More from this funder
- Funder identifier:
- 10.13039/100018270
- Grant:
- Aspire 2020
+ Stichting
Sanquin Bloedvoorziening
More from this funder
- Funder identifier:
- 10.13039/501100012023
- Grant:
- PPOC-12-012027
+ National
Institute for Health Research
More from this funder
- Funder identifier:
- 10.13039/501100000272
- Publisher:
- BMJ Publishing Group
- Journal:
- Archives of Disease in Childhood. Fetal and Neonatal Edition More from this journal
- Volume:
- 108
- Issue:
- 5
- Pages:
- fetalneonatal-2022
- Publication date:
- 2023-02-21
- DOI:
- EISSN:
-
1468-2052
- ISSN:
-
1359-2998
- Language:
-
English
- Keywords:
- Pubs id:
-
1331615
- Local pid:
-
pubs:1331615
- Source identifiers:
-
W4321613064
- Deposit date:
-
2026-05-05
- ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.
Terms of use
- Copyright date:
- 2023
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record